Atb Cap Markets Weighs in on Cresco Labs Q2 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Stock analysts at Atb Cap Markets issued their Q2 2025 earnings per share (EPS) estimates for shares of Cresco Labs in a note issued to investors on Wednesday, March 12th. Atb Cap Markets analyst F. Gomes forecasts that the company will post earnings per share of ($0.03) for the quarter. Atb Cap Markets has a “Hold” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Atb Cap Markets also issued estimates for Cresco Labs’ Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.03) EPS.

Cresco Labs Stock Performance

Shares of OTCMKTS CRLBF opened at $0.75 on Friday. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80. The firm’s 50-day moving average price is $0.89 and its two-hundred day moving average price is $1.20. Cresco Labs has a 52-week low of $0.70 and a 52-week high of $2.60. The stock has a market capitalization of $364.25 million, a P/E ratio of -3.73 and a beta of 1.79.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.